NCT00161616View on ClinicalTrials.gov

Study Evaluating InductOs in Diaphyseal Tibia Fractures

PHASE4CompletedINTERVENTIONAL

Enrollment

277

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

July 31, 2008

Study Completion Date

August 31, 2008

Conditions

Tibial Fractures

Interventions

DRUG

InductOs

InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage

Trial Locations (27)

5021

Bergen

7505

Cape Town

7925

Cape Town

9000

Ghent

9300

Bloemfontein

13353

Berlin

14461

Bucharest

15276

Bialystok

20520

Turku

20954

Lublin

21659

Bucharest

27100

Pavia

28805

Alcalá

31400

Toulouse

41200

Sosnowiec

48149

Münster

50098

Bucharest

55131

Mainz

71252

Szczecin

94010

Créteil

00168

Roma

3015 GD

Rotterdam

0407

Oslo

0157

Centurion

Unknown

Durban

BS2 8HW

Bristol

NR4 7 UY

Norwich

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00161616 - Study Evaluating InductOs in Diaphyseal Tibia Fractures | Biotech Hunter | Biotech Hunter